Correction: impact of TP53 codon 72 and MDM2 SNP 309 polymorphisms in pancreatic ductal adenocarcinoma.

Fig 1, Fig 2, and Fig 4 appear incorrectly in both the HTML and PDF versions of this article. Please view the corrected versions of Fig 1, Fig 2, and Fig 4 here.

Fig 1

Distribution of TP53 codon 72 genotypes among pancreatic ductal adenocarcinoma (PDAC) patients, chronic pancreatic (CP) patients and normal controls.

The p-value was calculated by comparing the Pro/Pro genotype between PDAC patients and normal controls and between CP patients and normal controls.

Fig 2

Distribution of MDM2 single-nucleotide polymorphism (SNP) 309 genotypes among pancreatic ductal adenocarcinoma (PDAC) patients, chronic pancreatitis (CP) patients and normal controls.

The p-value was calculated by comparing the G/G genotype between PDAC patients and normal controls and between CP patients and normal controls.

Fig 4

Clinicopathological correlations of TP53 and MDM2 protein expression in pancreatic ductal adenocarcinoma (PDAC) patients, chronic pancreatitis (CP) patients and normal controls.